SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

A strong quarterly report, led by rapid growth in SpaceXs AI compute business and its first profit since its IPO, is driving attention; traders are largely bullish, while some question the valuation and heavy capital spending and flag upcoming share unlocks as a risk.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micros preliminary fiscal Q1 update raised its revenue and gross-margin outlook well above prior guidance, citing stronger AI-platform demand, and sparked a sharp after-hours rally. Many traders view the update as evidence of robust AI-server demand and see the shares as undervalued, while others question whether the gains will hold given past execution concerns and the stocks volatility.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs earnings beat was overshadowed by softer fourth-quarter guidance, slowing revenue growth and a reduced advertising outlook, prompting a sharp selloff. Traders are debating whether the drop reflects worsening growth prospects or an overreaction to the outlook, with some pointing to continued profitability as a reason to buy the dip.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla and SpaceX have formed committees to explore a potential merger, fueling speculation and bullish reactions; traders also question whether a deal will happen and whether Teslas earnings can support the stocks strength. The merger discussions remain preliminary, with no agreement or certainty of a transaction.

SK hynix, Inc. engages in the design, manufacture, and sale of semiconductor products. Its products include dynamic random access memory, not-AND flash memory, and multi-chip package. The company was founded on October 15, 1949 and is headquartered in Icheon, South Korea.

SK Hynix Inc - ADR

SK Hynix is being swept up in a sharp memory-chip and Korean-market selloff, with traders citing KOSPI weakness, foreign selling, and fears about Chinese competition and the durability of the AI-driven memory cycle. Bulls argue the decline is excessive given strong memory demand and low valuations, while bears see further downside risk from cyclical and oversupply concerns.

Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. It develops and commercializes molecular tests that help patients and providers uncover genetic insights. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Myriad Genetics, Inc.

Myriads agreement to sell its prenatal-testing business to Labcorp for cash is driving a sharp rally, with bullish traders viewing the proceeds as balance-sheet support and funding for oncology testing. Others question the deal, arguing that shedding a revenue-generating unit could leave a weaker business and persistent debt and execution concerns.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy is in focus ahead of its Q3 report, as traders debate whether AI and data-center power demand can support its elevated valuation after a sharp, volatile pullback. Bulls expect results and guidance to validate the growth story, while skeptics point to stretched expectations and broader AI-market pressure as risks.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

The FDAs acceptance of REZZAYOs supplemental application for Priority Review is drawing attention, with traders focused on a possible expansion into invasive-fungal-disease prevention and the pending FDA decision. Optimism about that opportunity is tempered by concerns over DefenCath reimbursement and adoption, management execution, and the stocks muted response to positive developments.

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Rapport Therapeutics Inc.

Rapport Therapeutics Inc

Rapports Phase 2 RAP-219 trial in acute bipolar mania met its primary and secondary endpoints, drawing attention to the drugs potential beyond epilepsy. Traders are divided: bulls view the results as validation of the pipeline, while skeptics point to the modest placebo-adjusted benefit and higher agitation-related side effects and discontinuations as reasons the initial enthusiasm faded.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Reported orders from ByteDance, Alibaba, and Tencent for export-compliant Nvidia graphics cards are drawing attention amid U.S. restrictions on more advanced chips. Traders see the orders as evidence of continued Chinese demand, but some are frustrated that the shares have shown little response and question how much Nvidia can deliver given reported supply constraints.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SPRY FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against ARS Pharmaceuticals Inc. ("ARS Pharmaceuticals or the Company) (NASDAQ: SPRY) and reminds investors of the October 5, 2026 deadline to seek the role of lead plaintiff in a federal securities...

ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRY

ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRY ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRYPR NewswireNEW YORK, Oct. 5, 2026NEW YORK, Oct. 5, 2026...

SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law

SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS LawPR NewswireLOS ANGELES, Oct. 5, 2026LOS ANGELES, Oct. 5, 2026 /PRNewswire/ -- Schall, Brown...

ARS Pharmaceuticals Deadline: SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit

ARS Pharmaceuticals Deadline: SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit ARS Pharmaceuticals Deadline: SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud LawsuitPR NewswireNEW YORK, Oct. 2, 2026NEW YORK, Oct. 2, 2026...

SPRY SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026

SPRY SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026 SPRY SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026PR...

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in ARS Pharmaceuticals Inc. Lawsuit - SPRY

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in ARS Pharmaceuticals Inc. Lawsuit - SPRY Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in ARS Pharmaceuticals Inc. Lawsuit - SPRYPR NewswireNEW YORK, Sept. 30, 2026Wall...

SPRY Deadline: SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit

SPRY Deadline: SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit SPRY Deadline: SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud LawsuitPR NewswireNEW YORK, Sept. 28, 2026 NEW YORK, Sept. 28, 2026 /PRNewswire/ -- Why:Rosen...

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - SPRY

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - SPRY INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action...

SPRY Shareholder Alert: October 5, 2026 Lead Plaintiff Deadline in ARS Pharmaceuticals Inc. Securities Class Action - Contact SueWallSt

SPRY Shareholder Alert: October 5, 2026 Lead Plaintiff Deadline in ARS Pharmaceuticals Inc. Securities Class Action - Contact SueWallSt SPRY Shareholder Alert: October 5, 2026 Lead Plaintiff Deadline in ARS Pharmaceuticals Inc. Securities Class Action - Contact SueWallStPR NewswireNEW YORK, Sept...

SPRY UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026

SPRY UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026 SPRY UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026PR...

ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. Its product includes Epinephrine Nasal Spray. The company was founded by Richard Lowenthal, Robert Bell, and Sarina Tanimoto on August 5, 2015 and is headquartered in San Diego, CA.

ARS Pharmaceuticals Inc

SPRY, PASG, BOXL: Why These Stocks Plunged Double Digits In After-Hours Trading Today

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>ARS Pharmaceuticals shares tumbled after the company said Neffy failed to secure expanded commercial insurance coverage for the July 1 review cycle.&nbsp;</li><li>Passage Bio shares fell after the company agreed to merge with Remix Therapeutics in an all-stock deal.</li><li>Boxlight shares dropped after hours following a speculative rally fueled by the company's recent 1-for-6 reverse stock split.&nbsp;</li></ul>ARS Pharmaceuticals (SPRY), Passage Bio (PASG), and Boxlight Corp. (BOXL),&nbsp;all small-cap stocks, posted double-digit losses in after-hours trading on Wednesday as investors digested new business developments.<h2 class="st-heading-2">SPRY Faces Coverage Setback</h2>ARS Pharmaceuticals shares came under heavy selling after investors reacted to an <a href="https://stocktwits.com/news-articles/markets/equity/spry-stock-tanks-after-hours-ars-pharmaceuticals-reports-no-new-major-insurance-wins-for-neffy/cZK6ySGR7Q4">update</a> on insurance coverage for Neffy, the company's needle-free treatment for severe allergic reactions.&nbsp;The stock fell after the company said talks with health insurers did not lead to broader coverage for the July 1 review cycle. Investors saw the setback as a challenge to sales growth and increased product use.&nbsp;Commercial insurance support often plays a major role in determining how quickly newly approved therapies gain traction. Additionally, the company lowered its projected 2026 cash-based operating expense forecast to approximately $248 million.&nbsp;<a href="https://stocktwits.com/symbol/SPRY">ARS Pharmaceuticals’ stock</a> traded over 24% lower overnight. On Stocktwits, retail sentiment around the stock&nbsp;improved to ‘neutral’ from ‘bearish’ the previous day.&nbsp;<h2 class="st-heading-2">PASG Drops Following Deal Announcement</h2>Passage Bio declined after unveiling a <a href="https://stocktwits.com/news-articles/markets/equity/pasg-stock-slumps-after-hours-whats-driving-the-selloff/cZKyoZ4R7Q5">merger</a> agreement involving Remix Therapeutics, Inc. The companies have agreed to combine through an all-stock transaction that will create a publicly traded biotechnology company focused on RNA-processing therapies.&nbsp;The merged business plans to operate as Remix Therapeutics and list its shares on Nasdaq under the ticker symbol RMTX following the completion of the deal with existing Passage Bio shareholders expected to own roughly 7% of the combined entity.&nbsp;The transaction is accompanied by an oversubscribed private financing expected to generate approximately $100 million in gross proceeds from a group of investors led by Decheng Capital.<a href="https://stocktwits.com/symbol/PASG">Passage Bio stock</a> traded over 15% lower overnight. Retail sentiment around the stock improved to ‘extremely bullish’ from ‘bullish’ territory the previous day.&nbsp;<h2 class="st-heading-2">Post-Split Volatility Drives Sharp Reversal In BOXL After Massive Rally&nbsp;</h2>Boxlight shares pulled back in after-hours trading after jumping 37% during the regular session. The education technology company, which recently&nbsp;completed a reverse stock split to remain listed on Nasdaq, saw investors take profits after a surge driven by heavy speculative buying.&nbsp;The decline followed a daytime surge that pushed shares significantly higher before momentum faded. Traders appeared to reassess positions after a rapid advance fueled by heavy volume and a reduced share count.On Monday, Boxlight implemented a 1-for-6 reverse stock split, which reduced the number of authorized Class A shares, creating a much tighter trading float and increasing the stock’s sensitivity to buying and selling activity.<a href="https://stocktwits.com/symbol/BOXL">Boxlight stock</a> traded over 17% lower overnight. Retail sentiment around the stock jumped to ‘extremely bullish’ from ‘neutral’ territory the previous day.&nbsp;So far this year, PASG and BOXL stocks have plunged 50% and 52%, respectively, while SPRY stock has declined 9%.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/pfe-stock-continues-to-drop-as-lung-cancer-trial-disappointment-overshadows-ibrance-win/cZKyn58R7Qc">PFE Stock Continues To Drop As Lung Cancer Trial Disappointment Overshadows Ibrance Win</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

ProKidney (PROK) is developing rilparencel, an autologous cellular therapy aimed at slowing kidney function decline in patients with chronic kidney disease/ Photo credit: Getty Images

ARS Pharmaceuticals (SPRY), Passage Bio (PASG), and Boxlight Corp. (BOXL),&nbsp;all small-cap stocks, posted double-digit losses in after-hours trading on Wednesday as investors digested new business developments.

The after-hours decline was driven by concerns over trading activity, business performance and company restructuring plans. 


Boxlight Corp

Passage Bio Inc

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$4.29
Prev Close	$4.23
Open	$4.25
Dividend Yield	0.00%
50-Day Moving Average	$4.92
Beta	1.18
Avg. Volume	1.42M
PE Ratio	-1.97

52-Week High	$13.15
52-Week Low	$3.81
Market Capitalization	$420.66M
EPS (Annual)	-$1.74
Price to Book	34.09
Revenue Per Employee	$517,042.95

Feed

News

Sentiment

Earnings

Fundamentals

Info

SPRY Fundamentals